Akebia Therapeutics, Inc. (NASDAQ:AKBA) SVP Steven Keith Burke Sells 50,506 Shares

Akebia Therapeutics, Inc. (NASDAQ:AKBA) SVP Steven Keith Burke sold 50,506 shares of the stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $2.10, for a total value of $106,062.60. Following the completion of the transaction, the senior vice president now owns 816,234 shares in the company, valued at approximately $1,714,091.40. The trade was a 5.83 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

Akebia Therapeutics Stock Up 1.4 %

Shares of Akebia Therapeutics stock opened at $2.17 on Thursday. The company has a market cap of $473.45 million, a PE ratio of -9.43 and a beta of 0.74. Akebia Therapeutics, Inc. has a 52 week low of $0.80 and a 52 week high of $2.48. The business has a 50 day moving average price of $2.00 and a 200-day moving average price of $1.67.

Akebia Therapeutics (NASDAQ:AKBA) last issued its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.06). The business had revenue of $37.43 million during the quarter, compared to analyst estimates of $45.66 million. During the same quarter in the previous year, the business posted ($0.08) EPS. As a group, research analysts anticipate that Akebia Therapeutics, Inc. will post -0.3 EPS for the current year.

Analyst Ratings Changes

AKBA has been the topic of a number of recent research reports. StockNews.com cut Akebia Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, January 15th. HC Wainwright reiterated a “buy” rating and set a $7.50 price objective on shares of Akebia Therapeutics in a report on Thursday, January 23rd.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Barclays PLC increased its stake in Akebia Therapeutics by 276.1% in the 3rd quarter. Barclays PLC now owns 273,085 shares of the biopharmaceutical company’s stock valued at $360,000 after buying an additional 200,482 shares during the last quarter. Wellington Management Group LLP bought a new position in shares of Akebia Therapeutics in the third quarter valued at approximately $534,000. BNP Paribas Financial Markets increased its position in shares of Akebia Therapeutics by 205.8% during the third quarter. BNP Paribas Financial Markets now owns 46,270 shares of the biopharmaceutical company’s stock valued at $61,000 after acquiring an additional 31,137 shares during the last quarter. XTX Topco Ltd bought a new stake in Akebia Therapeutics during the third quarter worth $58,000. Finally, State Street Corp boosted its position in Akebia Therapeutics by 24.9% in the third quarter. State Street Corp now owns 3,430,527 shares of the biopharmaceutical company’s stock worth $4,528,000 after purchasing an additional 683,287 shares during the last quarter. 33.92% of the stock is owned by institutional investors.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.